Diagnosis & Disease Information

Cavity shaving halved the rates of positive margins and reexcision among patients undergoing partial

Neratinib May Be Efficacious for Treatment of HER2-Positive Breast Cancer

By

Jonathan Goodman, MPhil

July 13, 2016

Neratinib demonstrated clinical efficacy for patients with HER2-positive, hormone-receptor-negative breast cancer, in a phase 2 study.

Next post in Breast Cancer

Patients with HER2-positive early-stage breast cancer who received neratinib had improved invasive a

Novel Agents Show Promise Against Endocrine-resistant Breast Cancer